Initial Estimates of the Minimal Clinically Important Difference (MCID) for the

Neuropathic Pain Symptom Inventory (NPSI): A Systematic Meta-Analysis

Authors: Alexandra Canori, PhD[1], Rebecca Howard, MD[1], Jeffrey Bower, PhD[2], David Putrino,

PhD[1], and Laura Tabacof, MD[1]

[1] Department of Rehabilitation and Human Performance, Icahn School of Medicine at Mount

Sinai, New York, NY

[2] Sana Health Inc.

RUNNING TITLE: MCID FOR THE NPSI

Corresponding Author: Dr. Jeffrey Bower

• Email: jeff@sana.io

• Phone: 951-236-3007

• Institution URL: https://www.sana.io/

• Address:

Sana Health, Inc. Attn: Jeffrey Bower

2051 Dogwood St Ste. 220

Louisville, CO 80027

Abstract:

Objective:

The Neuropathic Pain Symptom Inventory (NPSI) is commonly used assessment in Neuropathic

Pain (NP) trials, yet a Minimal Clinically Important Difference (MCID) has not been established.

A MCID would enhance the interpretability of NPSI scores, guiding clinicians and researchers in

assessing clinically important improvements in NP symptoms. The aim of this study was to

calculate an MCID from the available scientific research that used the NPSI.

Methods:

We conducted a systematic review and meta-analysis of NP trials reporting the NPSI. Three

distributional approaches were applied to estimate the MCID: pooled standard deviation (SD) of

change scores, pooled baseline SD, and a random-effects meta-analytic approach. Only

treatments arms within RTCs were examined. Treatment arms were grouped by NP etiology,

enabling etiology-specific MCID estimates. Bias for each included study was assessed using the

Cochrane tool for quality assessment of randomized controlled trials.

Results:

323 trials were examined, 12 were selected for inclusion for a total of 17 treatment arms. The

calculated MCID estimates for the NPSI total score were 7.95 using pooled SD of change scores,

7.73 using pooled baseline SD, and 6.85 using the random-effects method. Etiology-specific

MCIDs varied, with Post-Infectious conditions and Diabetic Peripheral Neuropathy showing

higher values than other NP types.

Conclusion:

This study provides preliminary MCID estimates for the NPSI. Limitations include limited data

for certain NP subtypes, highlighting the need for additional anchor-based and etiology-specific

MCID research to refine these estimates. These findings can aid in future NP trial design and the

interpretation of results.

Key Words:

Neuropathic Pain, Neuropathic Pain Symptom Inventory, NPSI, Minimal Clinically Important

Difference, MCID

Introduction:

Clinical trials have historically focused on establishing statistical significance as the main

measure of clinical success. However, statistical significance does not indicate if the amount of

improvement was large enough to be considered clinically meaningful. It is imperative for

researchers and clinicians to communicate the clinical importance of their findings to accurately

assess its utility to patients. This is especially important when evaluating conditions like

neuropathic pain (NP), a multifaceted and chronic disorder that is diverse in causes and etiology,

often causing considerable suffering and distress in patients.

Neuropathic pain is defined by the International Association for the Study of Pain as pain caused

by a lesion or disease of the somatosensory nervous system resulting from complex

pathophysiological mechanisms involving both peripheral and central nervous system

dysfunctions [1]. NP affects roughly 10% of the general population and causes a decrease in

quality of life and high healthcare costs, with the economic burden of neuropathic pain estimated

to be significant due to both direct medical expenses and loss of productivity [2,3,4]. NP can

either be spontaneous or evoked by stimuli, and presents with negative (e.g. numbness), or

positive (e.g. parasthesia) symptoms [5]. To definitively diagnose NP, there must be evidence of

damage to the nervous system, through radiological, neurophysiological, or tissue testing,

accompanying a neuroanatomically accurate pain pattern. Chronic NP is defined as pain lasting

at least 3 months and can be divided into peripheral or central etiologies [6]. Peripheral etiologies

include diabetic neuropathy, postherpetic neuralgia, and radiculopathy [3]. Central etiologies

include brain injury or spinal cord injury mediated, and post-stroke pain.

NP treatments span a wide range and includes anticonvulsive, antidepressant, or opiate analgesic

medications as well as topical medications, surgical procedures, and neuromodulation.

Evaluating the effectiveness of a diverse set of new and existing interventions is important to

inform clinicians on effective treatment options [7]. NP can be assessed using standardized

questionnaires, clinical examinations, and patient-reported symptoms. Reported symptoms such

as burning, tingling, numbness, spontaneous pain, and sensory abnormalities support the

diagnosis. Questionnaires can be categorized as screening questionnaires (for identifying patients

with NP and distinguishing from non-neuropathic pain) and assessment questionnaires (for

measuring symptoms and treatment response) [8].

The Neuropathic Pain Symptom Inventory (NPSI) is an assessment questionnaire that has gained

popularity in NP trials due to its capacity to characterize neuropathic symptoms and to monitor

treatment effectiveness [8,9]. The survey was developed in 2004 and assesses both the

quantitative and qualitative properties of NP as a patient-reported outcome (PRO) [10]. It has

been validated in more than 10 different languages for patients with both peripheral and central

neuropathic pain [9]. It includes 12 items (10 descriptors of symptoms and 2 items for duration

of spontaneous or paroxysmal pain) that categorize pain into 5 subscales of NP: burning pain,

evoked pain, pressing pain, paroxysmal pain, and paresthesia/dysesthesia. These subscales can

be examined individually or a total score can be computed that assesses overall NP severity. The

NPSI total is calculated by summing the 10 descriptor items for a total score of 0-100, with

higher scores indicating greater severity. The NPSI is a relatively new scale that is being used

more frequently in trials of NP due to is excellent psychometric properties as well as its ability to

assess sub-domains of NP with its subscales. PROs like the NPSI align with the FDA's 2022

guidance on integrating patients' perspectives and using them as valid scientific evidence for

assessing clinically relevant symptoms and improvement resulting from an intervention [11].

The Minimal Clinical Important Difference (MCID) is defined as the smallest difference in the

instrument score that patients consider meaningful or beneficial [12]. It is particularly useful

when evaluating PROs and maintains a patient-centered approach to evaluating clinical trials,

allowing for identification of 'responders' to an intervention [13]. The MCID is a value used to

assess the clinical relevance of a result that is not captured in the statistical comparison of means

[12]. While statistical tests assess whether a difference exists, they do not necessarily indicate

whether that difference was meaningful to patients. Statistical significance is heavily influenced

by sample size, where a larger sample can make even small differences statistically significant

[14]. In clinical trials, it is not uncommon to observe statistically significant results that are not

of a magnitude that indicates a clinical improvement [13]. An MCID provides a criterion

researchers can use to evaluate observed improvements from an intervention and provide a

clearer picture of clinical importance.

In the absence of an a-priori MCID value from an external source, the FDA recommends the

calculation of the MCID using the anchor method [15]. The anchor method is preferred as its

estimate of MCID is determined by relating change on the PRO to an established measure of

global improvement. Distributionally based MCIDs are only used in preference to anchor based

when the latter is not available [16]. Distributionally based MCIDs have the disadvantages of

being disconnected from any other measure of improvement and they tend to align with more

with statistical significance, such that a trial with a statistically significant result will often

calculate a MCID that is less than their reported change, which does not add much information

about clinical importance. This can be remedied somewhat by using MCID estimates that are

external to the trial being conducted and are either from earlier pilot trials or from published

research. An advantage of distributional methods is that they can often be calculated from

reported statistics in published manuscripts, while calculating an MCID based on the anchor

method, subject-by-subject data is necessary, and thus, cannot be calculated based on published

results data. To estimate an MCID for the NPSI total based on published trials, using a

distributional method will be necessary.

There are several distributional methods however most of them involve quantifying the variance

of change scores from pre-post intervention. Some of the most common are using the Standard

Error of the Mean as the MCID or by multiplying the SD of Change by a value chosen from a

range of 0.25 to 0.5. The most common approach is to take ½ of a standard deviation of the

change score of a treatment group within a trial [13]. It has been found that ½ a standard

deviation corresponds to MCIDs calculated within a variety of trials, is highly correlated to using

SEM as the MCID, and may represent the limits of human discrimination ability [17]. For this

meta-analysis, we have determined that ½ a standard deviation is an appropriate value to use.

As of November 2024, no established MCID exists for the NPSI Total Score. The aim of this

meta-analysis was to calculate an MCID from the available scientific research that used the NPSI

to measure treatment response. Understanding the amount of change needed in the NSPI score

for a clinically important improvement in NP symptoms will help clinicians and scientists to

evaluate the effectiveness of previously published interventions and inform future trial design for

new NP treatments.

Materials and Methods:

Literature Search:

PubMed and Google Scholar databases were systematically searched for all relevant studies until

October 2024. A literature search was performed using the following search terms:

("Neuropathic Pain Symptom Inventory"[Title/Abstract] OR "NPSI"[Title/Abstract]) AND

("randomized controlled trial"[Publication Type] OR "clinical trial"[Publication Type]). No

restriction on publication dates was applied. A preliminary screening of titles and abstracts was

followed by a review of full-text articles, which informed subsequent study selection.

Selection Criteria:

Clinical trials and randomized controlled trials that evaluated changes in pain using the NPSI in

adults over the age of 18 were included. Case reports, abstracts, reviews, editorials, and

publications that were unavailable in English were excluded during screening. During full-text

review, studies were excluded for containing duplicate data, insufficient data to calculate overall

NPSI score or change in NPSI score, or missing statistical values. One included study used the

validated Thai version of the NPSI, all other included studies used the English version. The

exclusion process is outlined by the PRISMA flowchart in Figure 1.

Figure 1: PRISMA flowchart

Data Extraction and Quality Assessment:

Two investigators extracted title, author, publication date, study design, patient population,

sample size, mean age, sex, intervention, follow-up period, and NPSI scores. Methodological

quality and confidence of each trial was assessed by reviewing methods of randomization,

allocation concealment, blinding, selective reporting, and other biases in accordance with the

Cochrane Risk of Bias (RoB) 2 tool for quality assessment of randomized controlled trials [18].

No review protocol is was created and the review was not registered.

Study Selection for Analyses:

Out of 323 papers in the initial search, 20 were examined to determine if they reported the

required summary statistics or if they were derivable from other reported values. Studies were

required to have reported either the SD of change or Baseline SD for the NPSI Total to be

included in one of the analyses. In addition, each study was checked to ensure that the NPSI was

calculated by convention (sum of 10 items). Within selected trials, only treatment arms were

included in the analyses and data from placebo, waitlist, or inactive sham were excluded. After

assessing the 20 articles, 12 were included in the final set for analysis with 17 treatment arms for

the analysis (Table 1).

Table 1: Treatment Arms included in analyses. SMD is the Standardized Mean Difference.

Article	Paired Analyses	Baseline Analysis	Imputation Note	Patient Population	Analysis Category	Study Design	Intervention	Treatment Duration	N	Baseline Sd	Mean Change	SD of Change	SMD
Rocha, et al, 2014[19]	Exclude	Include	~	Upper limb CRPS1	CRPS	RCT	Thoracic Sympathetic Block	12 months	17	7.83	1.9	~	~

Study													
Rocha et al., 2014[19]	Exclude	Include	Baseline SD converted from SEM and N	Upper limb CRPS1	CRPS	RCT	Stellate Ganglion Block	12 months	19	12.20	1	~	~
Hoerder et al., 2023[20]	Exclude	Include	~	DPN	DPN	RCT	Acupuncture	14 weeks	31	15.80	10.7	~	~
Todorovic et al., 2022[21]	Exclude	Include	~	DPN	DPN	Crossover RCT	Lidocaine Intravenous	60 minutes	17	19.50	~	~	~
Schlaeger, et al., 2017[22]	Exclude	Include	~	Sickle cell disease pain	Other Disease	RCT	Pregabalin	3 months	11	13.00	8.1	~	~
Culver et al., 2017[23]	Include	Include	~	Sarcoid-associated with small nerve fiber loss	Other Disease	RCT	Cibinetide 1mg	28 days	15	20.00	14.5	17.9	0.81
Culver et al., 2017[23]	Include	Include	~	Sarcoid-associated with small nerve fiber loss	Other Disease	RCT	Cibinetide 4mg	28 days	15	20.80	8.4	12.7	0.66
Culver et al., 2017[23]	Include	Include	~	Sarcoid-associated with small nerve fiber loss	Other Disease	RCT	Cibinetide 8mg	28 days	16	17.10	12.9	13.8	0.93
Rehm, Binder, & Baron, 2010[24]	Include	Include	Multiplied NPSI Total scores by 10 to match convention	Postherpetic neuralgia	Post Infectious	RCT	Lidocaine	4 weeks	50	15.80	16	17.3	0.92
Rehm, Binder, & Baron, 2010[24]	Include	Include	Multiplied NPSI Total scores by 10 to match convention	Postherpetic neuralgia	Post Infectious	RCT	Pregabalin	4 weeks	48	15.80	14	18.7	0.75
Raksakietisak et al., 2022[25]	Exclude	Include	Used Wan et al., (2014) method to convert medians and quartiles to baseline mean and SD[26]	Post-cervical spine surgery pain	Surgical	RCT	Nefopam	30 days	25	6.30	~	~	~

Study				Condition	Category	Design	Treatment	Duration	N				
Juhl, Karlsso, & Damsgaard 2016[27]	Include	Include	Change SD estimated from p-value of change, N, and mean change. Active p < 0.001 or estimated at p = 0.00099.	Post-mastectomy pain	Surgical	RCT	Fat Grafting	6 months	8	10.00	13.7	7.15	1.92
Martinez, et al, 2013[28]	Include	include	~	Post-discectomy radicular pain	Surgical	RCT	Minocycline	3 months	51	17.00	17	18	0.94
Ushida, et al., 2023[29]	Include	Exclude	~	SCI	Central Nervous System	RCT	Mirogabalin	14 weeks	150	~	12.0	15.47	~
Kim, et al., 2020[30]	Include	Include	~	Central neuropathic pain	Central Nervous System	RCT	Intermittent Theta Burst TMS	5 days	15	15.86	13	9.15	1.42
Wong, Widerstrom-Nog, & Field-Fote, 2022[31]	Include	Include	~	SCI	Central Nervous System	RCT	8-Dose Wholebody Vibration	2 weeks	8	15.00	10	5	2.00
Wong, Widerstrom-Nog, & Field-Fote, 2022[31]	Include	Include	~	SCI	Central Nervous System	RCT	16-Dose Wholebody Vibration	2 weeks	8	21.00	3	4	0.75

Articles in the final set of studies were categorized by the authors into treatment for 6 etiologies

of neuropathic pain to enable sub-set analyses as follows (number of trials in brackets):

• CRPS: Complex regional pain syndrome type (1)

• DPN: Diabetic Peripheral Neuropathy (2)

• Other Disease: Sarcoid-associated small nerve fiber loss (1), Sickle Cell Disease pain (1)

• Post Infectious: Post-Herpetic Neuralgia (1)

• Central Nervous System: Brain or spinal cord injury (3)

• Surgical: Post-mastectomy pain (1), Post-cervical spine surgery pain (1), Post-discectomy

radicular pain (1)

Table 1 lists the study characteristics for all included treatment arms and reported or derived

statistics. The Standardized Mean Difference (Mean-Change/SD-of-Change) was calculated for

any trial that that reported Mean-Change and SD-of-Change. Any adjustments necessary to

estimate missing values or to correct NPSI scaling are reported in the Imputation Note column in

Table 1 and were as follows:

• Rocha et al., 2014 [19]: The baseline SD was calculated using the reported Standard

Error of the Mean (SEM) and the sample size (N).

• Rehm, Binder, & Baron, 2010 [24]: The NPSI total score was multiplied by 10 to bring it

from 0-10 to a 0-100 score range.

• Raksakietisak et al., 2022 [25]: Reported baseline medians and quartiles were converted

in to the baseline SD using the method presented in Wan et al., (2014) [26]

• Juhl, Karlsso, & Damsgaard 2016 [27]: The active arm reported a p value of < 0.001 for

the improvement of the active arm over baseline. We estimated this to be a value p =

0.00099 and used the cumulative inverse distribution function to derive the T value for

the test of mean change > 0. From the T value the SEM of change could be estimated by

dividing the mean change by the T value. Finally, the SD of change was calculated by

multiplying the SEM of change by the square root of the N.

There was a heterogeneous set of treatments and treatment durations in the sample of selected

study arms. The interventions included pharmacological, nerve block, alternative,

neuromodulatory, and reconstructive treatments (see Table 1, Intervention column). Treatment

durations ranged from 1-hour single treatments to multiple dose regimens of up to 12 months.

The selected interventions were all from successful trials, where at least one of the treatment

arms was statistically different from control, thus the measures of change and variability reflect

those of a successful treatment. The inclusion of diverse interventions and treatments lengths into

the analyses limits the ability of to produce an aggregated MCID for any single treatment type.

The interpretation of the resulting MCID across this sample can be interpreted as the MCID for

successful treatments for the NPSI total across a diverse range of NP etiologies.

Analyses:

2 separate methods were employed to calculate the MCID for the NSPI. The first approach

replicates the method used by Watt et al. (2021), and first described by Furukawa et al., (2006),

to calculate distributionally based MCIDs for the clinical rating scale MMSE and ADAS-Cog

[32,33].

The first method calculates a pooled SD across the selected study arms by weighing each arms

variance by the arms sample size (N) (see Equation 1) such that arms with greater numbers of

participants are weighted more heavily. The pooled SD formula is typically applied to combine

the SD from 2 parallel arms in a Randomized Controlled Trial (RTC), however, it can be

extended to incorporate any number of treatment arms.

A pooled standard deviation was calculated across either all treatment arms or a categorical

subset using the following formula (Equation 1):

$$SD_{pooled} = \sqrt{\frac{\sum (n_i - 1)SD_i^2}{\sum (n_{i-1})}}$$

Where n_i is the number of participants and SD_i is the standard deviation from each treatment

arm. Once the SD$_{pooled}$ was calculated, the MCID was calculated as half of the SD$_{pooled}$ Value

(SD$_{pooled}$ * 0.5). This analysis method was used to calculate MCIDs based on both the paired SD

as well as the Baseline SD values.

For the analyses based on Equation 1, the SD of change is the most appropriate statistic to base a

MCID upon as it is directly associated with the distribution of change scores resulting from the

intervention. However, there is a limited amount of published data that reports the SD of change.

Clinical trials almost always report baseline SD. While this source of variance does not capture

any aspect of change resulting from the intervention, baseline SD captures variance inherent in

the PRO, and has been shown to be highly predictive of the SD of change, and is an appropriate

approximation for the calculation of an MCID [13,33,34].

The second approach employed random effect meta-analysis model to calculate the pooled effect

size, mean, and SD [35]. Meta-analyses summary statistics, such as the pooled effect size or

pooled mean change, are weighed by the variance of each study arm such that arms with lower

variance are weighed more heavily.

Details on the random effect model are as follows:

• Hedges G effect size was calculated for each trial arm, as well as for the final pooled

effect size.

• τ^2 was calculated across arms included in each analysis and used to compute study

weights (not reported,).

• Pooled Effect Size and Pooled Mean Change were calculated by dividing sum of the

individual arms statistics (mean change or SD of change) multiplied by the arm's weight

divided by the sum of weights. See Formula 2 below:

271
$$M^* = \frac{\sum_{i=1}^{k} W_i^* Y_i}{\sum_{i=1}^{k} W_i^*}$$

Where M^* is the Pooled Statistic (SD-Pooled or Mean-Change-Pooled), k is the number

of treatment arms, i denoted a specific treatment arm, W_i^* is the weighted random effect

model variance for the arm (i), and Y_i is the statistic being pooled (SD-of-Change or

Mean-Change) within each arm (i).

• The Pooled SD was derived by dividing the Pooled Mean Change by the Pooled Effect

Size. The formula for SMD is Mean-Change / SD-of-Change, by rearranging this formula

we can directly derive the Pooled SD.

• The MCID was calculated as half the Pooled SD (Pooled SD * 0.5)

The meta-analysis model was run for all trials that reported a mean change and SD of change, as

well as for each neuropathy category.

The quality assessment indicates an overall low risk of bias in 75% of the 12 articles included in

this. These findings are highlighted in Figures 2 and 3.

Figure 2: Summary of quality assessment analysis

Figure 3: Overview of quality assessment analysis for 12 articles included in this meta-analysis

Results:

Pooled SD Method – SD of Change:

The results for the SD of Change analyses are presented in Table 2. The results show that the

aggregated MCID across all arms that reported SD of change is 7.95 points on the NPSI total.

The range of MCIDs reported within each category were 7.24 to 9.

Table 2: Results of the Pooled-SD-Method – SD-of-Change

Category	**# of Arms**	**N**	**Pooled SD**	**MCID**
Total	11	384	15.91	7.95
Central Nervous System	4	181	14.48	7.24
Other Disease	3	46	14.94	7.47
Post Infectious	2	98	18	9
Surgical	2	59	17.04	8.52

300   *Pooled SD Method – Baseline SD*:

301   The results for the Baseline SD analyses are presented in Table 3. The results show that the

302   aggregated MCID across all arms that reported SD of change is 7.73 points on the NPSI total.

303   The range of MCIDs reported within each category were 3.65 to 9.14.

305   *Table 3: Results of the Pooled-SD-Method – Baseline-SD*

Category	**# of Arms**	**N**	**Pooled SD**	**MCID**
All Categories	15	303	15.45	7.72
CRPS	2	36	10.38	5.19
Central Nervous System	3	31	17.1	8.55
DPN	2	48	17.18	8.59
Other Disease	4	57	18.29	9.14
Post Infectious	2	98	15.8	7.9
Surgical	2	33	7.3	3.65

307   *Random Effect Meta-Analysis:*

308   The results for the random effect Meta-analysis are presented in Table 4. The results show that

309   the aggregated MCID across all arms indicates that the MCID is 6.85 points on the NPSI total.

310   The range of MCIDs reported within each category were 4.48 to 9.1.

319   *Table 4: Results of the random effect meta-analysis*

Category	# of Arms	N	Pooled Mean Change	Pooled SD of Change	Pooled Effect Size	MCID
All Categories	11	384	12.94	13.69	0.94	6.85
Other Disease	3	46	12	15.62	0.77	7.81
Post Infectious	2	98	15.03	18.19	0.83	9.1
Surgical	2	59	15.57	12.31	1.27	6.15
Central Nervous System	4	181	9.9	8.95	1.11	4.48

Discussion:

This meta-analysis has calculated three estimates of the MCID for the NPSI total score across a

range of NP treatments and etiologies. MCID values are critical in clinical research as they

provide a threshold to interpret whether observed improvements in symptom scales, such as the

NPSI, reflect clinically meaningful changes for patients. These values aid clinicians and

researchers in evaluating the practical impact of interventions and designing future trials.

The three methods examined in this meta-analysis produced similar estimates of the MCID. The

estimates were 7.95 for the pooled SD change score method, 7.73 for the pooled SD baseline

score method, and 6.85 for the random effect method. By using 3 separate methods, a

conservative estimate of MCID can be determined by taking the highest MCID value of the 3

methods, which in this case is 7.95. The difference between the largest and smallest MCID is 1.1

points suggesting that these estimates were highly similar across methods suggesting that these

results are approaching the true value. The pooled SD change score and random effects methods,

based on change scores and their variance, are directly related to the actual measured

improvement resulting from an intervention. In contrast, the baseline SD method is disconnected

from any measured improvements in a trial, however, captures the variance inherent in the NPSI.

Based on this reasoning, the baseline SD method is inherently more limited for producing an

accurate MCID. However, applying the baseline SD method enabled the inclusion of more data

and improved the robustness of MCID estimates across categories.

Examination of the sub-analyses of etiologies produces a different pattern of MCIDs depending

on the method used. Table 5 summarizes the MCIDs found across the three methods and shows

the average MCID by etiology.

Table 5: Aggregated and Mean MCID values across the 3 methods examined.

Etiology	Change Score MCID	Baseline MCID	Meta-Analytic MCID	Mean MCID
Central Nervous System	7.24	8.55	4.48	6.76
Other disease	7.47	9.14	7.81	8.14
Post-Infectious	9	7.9	9.1	8.67
Surgical	8.52	3.65	6.15	6.11
CRPS	~	5.19	~	5.19

| DPN | ~ | 8.59 | ~ | 8.59 |

Of the three methods, it can be observed in Table 5 above that the Baseline-SD method differed

from both Change-Score-SD and Meta-Analytic methods, the latter 2 of which were similar. This

can be explained by the Change-Score-SD and Meta-Analytic methods being based on change

scores. Although the Baseline-SD varied from the other methods, it produced MCID estimates

by etiology that were of similar values to the other 2 methods. This similarity supports the

assumption that baseline SD can be used in place of change-score SD for the calculation of

MCID. For this analysis, the baseline SD method was included to increase the number of study

arms included in the analysis as baseline SD is typically reported more often in RTCs than within

arm SD of change. CRPS and DPN did not have any published clinical trial that reported a

change SD, and thus the baseline method was needed to estimate MCID for these etiologies.

Table 5 computes the mean MCID across etiologies. Calculating the mean MCID per etiology

produces an aggregated MCID that is likely closer to the true MCID.

The nature of pain may contribute to the variation in MCID between etiologies. Neuropathic pain

is multifaceted, with a vast range of mechanisms and factors that contribute to patients'

symptoms, therefore an improvement in certain pain characteristics may affect quality of life

more than others. Changes in perceived intensity could affect the range, and thus the variance, of

reported total pain scores in PROs which in turn would modulate an MCID based on

distributional methods. For example, paroxysmal pain that feels like stabbing or electric shocks

may be perceived as more painful than paresthesia pain that feels like pins and needles or

tingling [36]. Paroxysmal NP is common in patients with post-surgical pain or CRPS, therefore a

modest improvement in pain is perceived as an impactful change by patients. In addition,

conditions that lead to central neuropathic pain or central sensitization of pain such as spinal cord

or brain injury, and CRPS, may also be felt more intensely than a small fiber or primarily

peripheral neuropathy from diabetes mellitus or sarcoidosis. This may be reflected by the

observation that the Central Nervous System, Surgical, and CRPS etiologies had the smallest

average MCIDs due to the possibility that they have an attenuated score range. Conversely,

patients with DPN are likely to experience paresthesias, meaning a more pronounced

improvement in pain may be required before is recognized as meaningful, suggesting greater

variability and that the MCID in these conditions may be larger than other etiologies. The NPSI

contains 5 subscales measuring specific symptom categories in NP such as burning pain,

pressing pain, paroxysmal pain, as well as paresthesia. Evaluating these NPSI subscales to

characterize pain for each NP etiology may confirm these explanations. For this meta-analysis

NPSI sub-scales were too infrequently reported to calculate individual MCIDs. Other factors

may also contribute to variation in MCID. Patients with chronic conditions are likely to

experience fluctuations in daily pain levels, which introduces a higher level of variance in the

sample, whereas post-surgical pain conditions are likely to improve more gradually over time,

however the timeframes of recovery vary.

The findings of this meta-analysis are pertinent for implementation of the NPSI in clinical care

and to facilitate the interpretation of clinical outcomes. Although the NPSI is a validated

assessment tool [8], a substantial number of screened studies used the NPSI to characterize pain.

While this suggests additional utility of the NPSI as a screening tool for classification, the NPSI

is underutilized as a primary outcome to quantify changes in neuropathic pain. The value of the

NPSI to discriminate distinct types of neuropathic pain for clinical evaluation is accepted,

however the NPSI is also advantageous for monitoring neuropathic pain as it is validated and

responsive to changes in each pain distinction [37].

Future research can improve the understanding of the MCID of the NPSI by publishing anchor-

based estimates based on their trial data [7]. In addition, as more trials are published,

distributionally and anchor-based estimates of MCID can be calculated that are specific to

interventions and etiologies.

As the NPSI continues to be used as a metric of improvement in intervention trials for NP,

understanding the MCID of this scale will become increasingly important. This meta-analysis

produced distribution based MCID estimates from currently available published intervention

trials. A limitation of this work is that since there are so few published trials using the NPSI each

etiology only had a few trial arms to base a MCID upon. In order to estimate a general MCID for

the NPSI it was necessary to aggregate across etiologies. However, treatment effects can be

modulated within an etiology and future targeted MCID estimates based on large samples of data

would allow more for precision in understanding the magnitude of clinical improvement within

NP subtypes. While this analysis included a highly heterogenous set of interventions this is not a

limitation as MCID values are not specific to an intervention, but rather to the scale itself. This

analysis succeeds at producing an initial broad estimate of the MCID for the NPSI within NP.

The results of this analysis are more relevant to the properties of the NPSI that indicate the

clinically important magnitude of improvement on this PRO for NP in general and are less

relevant for understanding the MCID of this scale for a specific NP etiology.

In conclusion, this meta-analysis has used distributional methods to produce estimates of the

MCID for the NPSI total that are general across the examined etiologies and interventions. These

estimates can be used to guide clinical trial design or to better understand the clinical importance

of published NPSI total results.

Acknowledgements:

Dr. Jeffrey Bower is a paid employee of Sana Health, Inc. There are no conflicts of interest with

any of the authors of this study. No sources of financial or other support to declare.

Additional material including analytic code, data extracted from individual studies, data for

excluded studies, and quality analysis are available from the authors upon reasonable request. No

review protocol is available. The review was not registered.

References:

1. Baron, R., Binder, A., & Wasner, G. (2010). Neuropathic pain: diagnosis,

pathophysiological mechanisms, and treatment. The Lancet Neurology, 9(8), 807-819

2. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. (2017). Global,

regional, and national incidence, prevalence, and years lived with disability for 328

diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global

Burden of Disease Study 2016. The Lancet, 390(10100), 1211-1259

3. Sadosky, A., McDermott, A. M., Brandenburg, N. A., & Strauss, M. (2013). A review of

the epidemiology of painful diabetic peripheral neuropathy, postherpetic neuralgia, and

less commonly studied neuropathic pain conditions. Pain Practice, 14(1), S56-S67.

https://doi.org/10.1111/papr.12050

4. van Hecke, O., Austin, S. K., Khan, R. A., Smith, B. H., & Torrance, N. (2014).

Neuropathic pain in the general population: a systematic review of epidemiological

studies. Pain, 155(4), 654-662

5. Treede, R.D., Rief, W., Barke, A., Aziz, Q., Bennett, M.I., Benoliel, R., Cohen, M.,

Evers, S., Finnerup, N.B., First, M.B. & Giamberardino, M.A., (2019). Chronic pain as a

symptom or a disease: the IASP Classification of Chronic Pain for the International

Classification of Diseases (ICD-11). pain, 160(1), 19-27

6. Scholz, J., Finnerup, N.B., Attal, N., Aziz, Q., Baron, R., Bennett, M.I., Benoliel, R.,

Cohen, M., Cruccu, G., Davis, K.D. & Evers, S., (2019). The IASP classification of

chronic pain for ICD-11: chronic neuropathic pain. PAIN, 160, 53–59.

7. Zhang, Y., Xu, L., Huang, Y. (2024). Update in the Treatment of Neuropathic Pain. In:

Ma, C., Huang, Y. (eds) Translational Research in Pain and Itch. Springer, Singapore.

https://doi.org/10.1007/978-981-99-8921-8_12

8. Attal, N., Bouhassira, D., & Baron, R. (2018). Diagnosis and assessment of neuropathic

pain through questionnaires. The Lancet Neurology, 17(5), 456-466.

9. Haanpää, M. L., Attal, N., Backonja, M., Baron, R., Bennett, M., Bouhassira, D., ... &

Treede, R. D. (2011). NeuPSIG guidelines on neuropathic pain assessment. PAIN®,

152(1), 14-27.

10. Bouhassira, D., Attal, N., Fermanian, J., Alchaar, H., Gautron, M., Masquelier, E., ... &

Boureau, F. (2004). Development and validation of the neuropathic pain symptom

inventory. Pain, 108(3), 248-257.

11. U.S. Food and Drug Administration. (2022, January 26). Principles for selecting,

developing, modifying, and adapting patient-reported outcome instruments for use in

medical device evaluation: Guidance for industry and Food and Drug Administration

staff, and other stakeholders. https://www.fda.gov/media/141565/download

12. Jaeschke, R., Singer, J., & Guyatt, G. H. (1989). Measurement of health status:

ascertaining the minimal clinically important difference. Controlled clinical trials, 10(4),

407-415.

13. Copay, A. G., Subach, B. R., Glassman, S. D., Polly Jr, D. W., & Schuler, T. C. (2007).

Understanding the minimum clinically important difference: a review of concepts and

methods. The Spine Journal, 7(5), 541-546.

14. Fritz, C. O., Morris, P. E., & Richler, J. J. (2012). Effect size estimates: Current use,

calculations, and interpretation. Journal of Experimental Psychology: General, 141(1), 2-

18. https://doi.org/10.1037/a0024338

15. McLeod, L. D., Coon, C. D., Martin, S. A., Fehnel, S. E., & Hays, R. D. (2011).

Interpreting patient-reported outcome results: US FDA guidance and emerging methods.

Expert review of pharmacoeconomics & outcomes research, 11(2), 163-169.

16. Howard, R., Phillips, P., Johnson, T., O'Brien, J., Sheehan, B., Lindesay, J., Bentham, P.,

Burns, A., Ballard, C., Holmes, C. & McKeith, I., (2011). Determining the minimum

clinically important differences for outcomes in the DOMINO trial. International journal

of geriatric psychiatry, 26(8), 812-817.

17. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality

of life. The remarkable universality of half a standard deviation. Med Care 2003;41:582–

92

18. Higgins, J. P. T., Altman, D. G., & Sterne, J. A. C. (Eds.). (2011). Chapter 8: Assessing

risk of bias in included studies. In J. P. T. Higgins & S. Green (Eds.), Cochrane handbook

for systematic reviews of interventions (Version 5.1.0). The Cochrane Collaboration.

Available from https://handbook-5-1.cochrane.org

19. de Oliveira Rocha, R., Teixeira, M.J., Yeng, L.T., Cantara, M.G., Faria, V.G., Liggieri,

V., Loduca, A., Müller, B.M., Souza, A.C. & de Andrade, D.C., (2014). Thoracic

sympathetic block for the treatment of complex regional pain syndrome type I: a double-

blind randomized controlled study. PAIN®, 155(11), 2274-2281.

20. Hoerder, S., Habermann, I.V., Hahn, K., Meyer-Hamme, G., Ortiz, M., Grabowska, W.,

Roll, S., Willich, S.N., Schroeder, S., Brinkhaus, B. & Dietzel, J. (2023). Acupuncture in

diabetic peripheral neuropathy-neurological outcomes of the randomized acupuncture in

diabetic peripheral neuropathy trial. World journal of diabetes, 14(12), 1813.

21. Todorovic, M.S., Frey, K., Swarm, R.A., Bottros, M., Rao, L., Tallchief, D., Kraus, K.,

Meacham, K., Bakos, K., Zang, X. & Lee, J.B., (2022). Prediction of individual analgesic

response to intravenous lidocaine in painful diabetic peripheral neuropathy: a

randomized, placebo-controlled, crossover trial. The Clinical journal of pain, 38(2), 65-

76.

22. Schlaeger, J. M., Molokie, R. E., Yao, Y., Suarez, M. L., Golembiewski, J., Wilkie, D. J.,

& Votta-Velis, G. (2017). Management of sickle cell pain using pregabalin: a pilot study.

Pain Management Nursing, 18(6), 391-400.

23. Culver, D.A., Dahan, A., Bajorunas, D., Jeziorska, M., van Velzen, M., Aarts, L.P.,

Tavee, J., Tannemaat, M.R., Dunne, A.N., Kirk, R.I. & Petropoulos, I.N., (2017).

Cibinetide improves corneal nerve fiber abundance in patients with sarcoidosis-

associated small nerve fiber loss and neuropathic pain. Investigative ophthalmology &

visual science, 58(6), BIO52-BIO60.

24. Rehm, S., Binder, A., & Baron, R. (2010). Post-herpetic neuralgia: 5% lidocaine

medicated plaster, pregabalin, or a combination of both? A randomized, open, clinical

effectiveness study. Current medical research and opinion, 26(7), 1607-1619.

25. Raksakietisak, M., Rushatamukayanunt, P., Wilaiwan, K., Homprasert, C., Nitising, A.,

Sawasdiwipachai, P., & Pantubtim, C. (2022). Postoperative analgesia of intraoperative

nefopam in patients undergoing anterior cervical spine surgery: A prospective

randomized controlled trial. Medicine, 101(43), e31296.

26. Wan, X., Wang, W., Liu, J., & Tong, T. (2014). Estimating the sample mean and

standard deviation from the sample size, median, range and/or interquartile range. BMC

Medical Research Methodology, 14(1), 135. https://doi.org/10.1186/1471-2288-14-135

27. Juhl, A. A., Karlsson, P., & Damsgaard, T. E. (2016). Fat grafting for alleviating

persistent pain after breast cancer treatment: a randomized controlled trial. Journal of

Plastic, Reconstructive & Aesthetic Surgery, 69(9), 1192-1202.

28. Martinez, V., Szekely, B., Lemarié, J., Martin, F., Gentili, M., Ammar, S.B., Lepeintre,

J.F., de Loubresse, C.G., Chauvin, M., Bouhassira, D. & Fletcher, D., (2013). The

efficacy of a glial inhibitor, minocycline, for preventing persistent pain after lumbar

discectomy: a randomized, double-blind, controlled study. PAIN®, 154(8), 1197-1203.

29. Ushida, T., Katayama, Y., Hiasa, Y., Nishihara, M., Tajima, F., Katoh, S., Tanaka, H.,

Maeda, T., Furusawa, K., Richardson, M. & Kakehi, Y., (2023). Mirogabalin for central

neuropathic pain after spinal cord injury: a randomized, double-blind, placebo-controlled,

phase 3 study in Asia. Neurology, 100(11), e1193-e1206.

30. Kim, J. K., Park, H. S., Bae, J. S., Jeong, Y. S., Jung, K. J., & Lim, J. Y. (2020). Effects

of multi-session intermittent theta burst stimulation on central neuropathic pain: a

randomized controlled trial. NeuroRehabilitation, 46(1), 127-134.

31. Wong, M. L., Widerstrom-Noga, E., & Field-Fote, E. C. (2022). Effects of whole-body

vibration on neuropathic pain and the relationship between pain and spasticity in persons

with spinal cord injury. Spinal cord, 60(11), 963-970.

32. Watt, J. A., Veroniki, A. A., Tricco, A. C., & Straus, S. E. (2021). Using a distribution-

based approach and systematic review methods to derive minimum clinically important

differences. BMC Medical Research Methodology, 21, 1-7.

33. Furukawa, T. A., Barbui, C., Cipriani, A., Brambilla, P., & Watanabe, N. (2006).

Imputing missing standard deviations in meta-analyses can provide accurate results.

Journal of clinical epidemiology, 59(1), 7-10.

34. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality

of life. The remarkable universality of half a standard deviation. Med Care 2003;41:582–

92

35. Borenstein, M., Hedges, L. V., Higgins, J. P. T., & Rothstein, H. R. (2021). Introduction

to meta-analysis (2nd ed.). John Wiley & Sons.

36. Backonja, M.M. & Stacey B. (2004). Neuropathic pain symptoms relative to overall pain

rating. J Pain, 5(9), 491-497.

37. Lucchetta, M., Pazzaglia, C., Padua, L., & Briani, C. (2011). Exploring neuropathic

symptoms in a large cohort of Italian patients with different peripheral nervous system

diseases. *Neurological Sciences*, *32*(3), 423–426.

Figure 1

Figure 2

Risk of bias domains

Study	D1	D2	D3	D4	D5	Overall
Ushida 2023	+	+	+	+	+	+
Rehm 2010	+	+	X	X	+	-
Culver 2017	+	-	+	+	+	+
Martinez 2013	+	+	+	+	+	+
Wong 2022	-	-	+	-	-	-
de Oliveira Rocha 2014	+	+	+	+	+	+
Schlaeger 2017	-	+	+	+	+	+
Hoerder 2023	+	+	+	+	+	+
Kim 2020	+	+	+	+	+	+
Todorovic 2022	+	+	+	+	+	+
Raksakietisak 2022	+	+	+	+	+	+
Juhl 2016	+	X	X	X	+	X

Domains:
D1: Bias due to randomisation.
D2: Bias due to deviations from intended intervention.
D3: Bias due to missing data.
D4: Bias due to outcome measurement.
D5: Bias due to selection of reported result.

Judgement

 High

 Some concerns

 Low

Figure 3